Parameswaran Hari, MD, MRCP

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Parameswaran Hari, MD, MRCP, shares key considerations for the treatment of patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses the current and potential future utility of ixazomib (Ninlaro) maintenance in multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.